Related Experiment Video
Updated: May 25, 2026

Assays for the Specific Growth Rate and Cell-binding Ability of Rotavirus
Published on: January 28, 2019
Economic evaluation of the national immunization program of rotavirus vaccination for children in Korea
Hye-Young Kang1, Ki Hwan Kim, Ji Hong Kim
1Yonsei University, College of Pharmacy, Yonsei Institute of Pharmaceutical Sciences, Incheon, Korea.
Insights
Rotavirus vaccination is a cost-effective strategy for Korea. It significantly reduces symptomatic cases and disease burden, making it a valuable public health intervention.
Area of Science:
- Public Health
- Health Economics
- Vaccinology
Background:
- Rotavirus diarrhea poses a significant health and economic burden.
- Developing an evidence-based national immunization program is crucial for disease prevention.
Purpose of the Study:
- To assess the cost-effectiveness of rotavirus vaccination in Korea.
- To inform the development of a national immunization program.
Main Methods:
- A Markov model was utilized to compare vaccination versus no vaccination.
- Korea-specific data on rotavirus epidemiology and economic burden were incorporated.
- Efficacy data from a clinical trial of RotaTeq® were used.
Main Results:
- Universal rotavirus vaccination is projected to prevent 181,238 symptomatic cases (63.2% reduction) over 5 years.
- The cost per case averted was estimated at 375,620 Korean Won (KW).
- The breakeven vaccine price was calculated to be 56,061 KW.
Conclusions:
- Rotavirus vaccination substantially reduces the disease burden in Korea.
- Universal rotavirus vaccination is a cost-effective public health strategy.
Abstract:
The authors assessed the cost-effectiveness of rotavirus vaccination to develop an evidence-based national immunization program in Korea. A Markov model was constructed to compare the costs and clinical outcomes of vaccination versus no vaccination. The birth cohort of 493189 infants in 2007 was followed until the age of 5 years. Korea-specific data for epidemiological characteristics and economic burden of rotavirus diarrhea were used for the modeled estimation. Efficacy of RotaTeq® was based on a recent clinical trial. Rotavirus vaccination would prevent 181238 symptomatic cases (reduction rate = 63.2%) over 5 years after birth. From the societal perspective, at a vaccination cost of 100000 Korean won (KW; 1 US$ ≈ 1200 KW) per dose, universal vaccination would cost 375 620 KW per case averted. The breakeven price of vaccine was 56061 KW. Rotavirus vaccination would reduce the burden of the disease substantially and be a cost-effective strategy to prevent rotavirus diarrhea in Korea.
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Excretion
Drug Dosing: Infants and Children
Vaccinations

